Management of pheochromocytomas and paragangliomas: Review of current diagnosis and treatment options

Varování

Publikace nespadá pod Filozofickou fakultu, ale pod Lékařskou fakultu. Oficiální stránka publikace je na webu muni.cz.
Autoři

EID Michal FOUKAL Jakub SOCHOROVÁ Dana TUČEK Štěpán STARÝ Karel KALA Zdeněk MAYER Jiří NĚMEČEK Radim TRNA Jan KUNOVSKÝ Lumír

Rok publikování 2023
Druh Článek v odborném periodiku
Časopis / Zdroj Cancer Medicine
Fakulta / Pracoviště MU

Lékařská fakulta

Citace
www https://onlinelibrary.wiley.com/doi/10.1002/cam4.6010
Doi http://dx.doi.org/10.1002/cam4.6010
Klíčová slova biomarkers; chemotherapy; molecular biology; prognostic factor; surgery; target therapy
Popis Pheochromocytomas (PCCs) are rare neuroendocrine tumors derived from the chromaffin cells of the adrenal medulla. When these tumors have an extra-adrenal location, they are called paragangliomas (PGLs) and arise from sympathetic and parasympathetic ganglia, particularly of the para-aortic location. Up to 25% of PCCs/PGLs are associated with inherited genetic disorders. The majority of PCCs/PGLs exhibit indolent behavior. However, according to their affiliation to molecular clusters based on underlying genetic aberrations, their tumorigenesis, location, clinical symptomatology, and potential to metastasize are heterogenous. Thus, PCCs/PGLs are often associated with diagnostic difficulties. In recent years, extensive research revealed a broad genetic background and multiple signaling pathways leading to tumor development. Along with this, the diagnostic and therapeutic options were also expanded. In this review, we focus on the current knowledge and recent advancements in the diagnosis and treatment of PCCs/PGLs with respect to the underlying gene alterations while also discussing future perspectives in this field.
Související projekty:

Používáte starou verzi internetového prohlížeče. Doporučujeme aktualizovat Váš prohlížeč na nejnovější verzi.